Use of18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma

Heather M. Imsande, Jessica M. Davison, Minh T. Truong, Anand K. Devaiah, Gustavo A. Mercier, Al J. Ozonoff, Rathan M. Subramaniam

Research output: Contribution to journalArticle

Abstract

OBJECTIVE. The purpose of this article is to establish whether pretreatment 18F-FDG uptake predicts disease-free survival (DFS) and overall survival in patients with head-and-neck non-squamous cell carcinoma (SCC). MATERIALS AND METHODS. Eighteen patients (six women and 12 men; mean [± SD] age at diagnosis, 57.89 ± 13.54 years) with head-and-neck non-SCC were included. Tumor FDG uptake was measured by the maximum standardized uptake value (SUVmax) and was corrected for background liver FDG uptake to derive the corrected SUVmax. Receiver operating characteristic analyses were used to predict the optimal corrected SUVmax cutoffs for respective outcomes of DFS (i.e., absence of recurrence) and death. RESULTS. The mean corrected SUVmax of the 18 head-and-neck tumors was 5.63 ± 3.94 (range, 1.14-14.29). The optimal corrected SUVmax cutoff for predicting DFS and overall survival was 5.79. DFS and overall survival were significantly higher among patients with corrected SUV max <6 than among patients with corrected SUVmax ≥ 6. The mean DFS for patients with corrected SUVmax <6 was 25.7 ± 11.14 months, and the mean DFS for patients with corrected SUV max ≥ 6 was 7.88 ± 7.1 months (p <0.018). Among patients with corrected SUVmax <6, none died, and the mean length of follow-up for this group was 35.2 ± 9.96 months. All of the patients who died had corrected SUVmax ≥ 6, and the overall survival for this group was 13.28 ±12.89 months (p <0.001). CONCLUSION. FDG uptake, as measured by corrected SUVmax, may be a predictive imaging biomarker for DFS and overall survival in patients with head-and-neck non-SCC.

Original languageEnglish (US)
Pages (from-to)976-980
Number of pages5
JournalAmerican Journal of Roentgenology
Volume197
Issue number4
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Biomarkers
Disease-Free Survival
Survival
Carcinoma, squamous cell of head and neck
Fluorodeoxyglucose F18
ROC Curve
Neoplasms
Neck
Head
Recurrence
Liver

Keywords

  • F-FDG PET/CT
  • Disease-free survival
  • Head and neck
  • Non-squamous cell carcinoma
  • Overall survival

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Imsande, H. M., Davison, J. M., Truong, M. T., Devaiah, A. K., Mercier, G. A., Ozonoff, A. J., & Subramaniam, R. M. (2011). Use of18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. American Journal of Roentgenology, 197(4), 976-980. https://doi.org/10.2214/AJR.10.4884

Use of18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. / Imsande, Heather M.; Davison, Jessica M.; Truong, Minh T.; Devaiah, Anand K.; Mercier, Gustavo A.; Ozonoff, Al J.; Subramaniam, Rathan M.

In: American Journal of Roentgenology, Vol. 197, No. 4, 10.2011, p. 976-980.

Research output: Contribution to journalArticle

Imsande, HM, Davison, JM, Truong, MT, Devaiah, AK, Mercier, GA, Ozonoff, AJ & Subramaniam, RM 2011, 'Use of18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma', American Journal of Roentgenology, vol. 197, no. 4, pp. 976-980. https://doi.org/10.2214/AJR.10.4884
Imsande, Heather M. ; Davison, Jessica M. ; Truong, Minh T. ; Devaiah, Anand K. ; Mercier, Gustavo A. ; Ozonoff, Al J. ; Subramaniam, Rathan M. / Use of18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma. In: American Journal of Roentgenology. 2011 ; Vol. 197, No. 4. pp. 976-980.
@article{729390628b27435595f31b14e934e10b,
title = "Use of18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma",
abstract = "OBJECTIVE. The purpose of this article is to establish whether pretreatment 18F-FDG uptake predicts disease-free survival (DFS) and overall survival in patients with head-and-neck non-squamous cell carcinoma (SCC). MATERIALS AND METHODS. Eighteen patients (six women and 12 men; mean [± SD] age at diagnosis, 57.89 ± 13.54 years) with head-and-neck non-SCC were included. Tumor FDG uptake was measured by the maximum standardized uptake value (SUVmax) and was corrected for background liver FDG uptake to derive the corrected SUVmax. Receiver operating characteristic analyses were used to predict the optimal corrected SUVmax cutoffs for respective outcomes of DFS (i.e., absence of recurrence) and death. RESULTS. The mean corrected SUVmax of the 18 head-and-neck tumors was 5.63 ± 3.94 (range, 1.14-14.29). The optimal corrected SUVmax cutoff for predicting DFS and overall survival was 5.79. DFS and overall survival were significantly higher among patients with corrected SUV max <6 than among patients with corrected SUVmax ≥ 6. The mean DFS for patients with corrected SUVmax <6 was 25.7 ± 11.14 months, and the mean DFS for patients with corrected SUV max ≥ 6 was 7.88 ± 7.1 months (p <0.018). Among patients with corrected SUVmax <6, none died, and the mean length of follow-up for this group was 35.2 ± 9.96 months. All of the patients who died had corrected SUVmax ≥ 6, and the overall survival for this group was 13.28 ±12.89 months (p <0.001). CONCLUSION. FDG uptake, as measured by corrected SUVmax, may be a predictive imaging biomarker for DFS and overall survival in patients with head-and-neck non-SCC.",
keywords = "F-FDG PET/CT, Disease-free survival, Head and neck, Non-squamous cell carcinoma, Overall survival",
author = "Imsande, {Heather M.} and Davison, {Jessica M.} and Truong, {Minh T.} and Devaiah, {Anand K.} and Mercier, {Gustavo A.} and Ozonoff, {Al J.} and Subramaniam, {Rathan M.}",
year = "2011",
month = "10",
doi = "10.2214/AJR.10.4884",
language = "English (US)",
volume = "197",
pages = "976--980",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "4",

}

TY - JOUR

T1 - Use of18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma

AU - Imsande, Heather M.

AU - Davison, Jessica M.

AU - Truong, Minh T.

AU - Devaiah, Anand K.

AU - Mercier, Gustavo A.

AU - Ozonoff, Al J.

AU - Subramaniam, Rathan M.

PY - 2011/10

Y1 - 2011/10

N2 - OBJECTIVE. The purpose of this article is to establish whether pretreatment 18F-FDG uptake predicts disease-free survival (DFS) and overall survival in patients with head-and-neck non-squamous cell carcinoma (SCC). MATERIALS AND METHODS. Eighteen patients (six women and 12 men; mean [± SD] age at diagnosis, 57.89 ± 13.54 years) with head-and-neck non-SCC were included. Tumor FDG uptake was measured by the maximum standardized uptake value (SUVmax) and was corrected for background liver FDG uptake to derive the corrected SUVmax. Receiver operating characteristic analyses were used to predict the optimal corrected SUVmax cutoffs for respective outcomes of DFS (i.e., absence of recurrence) and death. RESULTS. The mean corrected SUVmax of the 18 head-and-neck tumors was 5.63 ± 3.94 (range, 1.14-14.29). The optimal corrected SUVmax cutoff for predicting DFS and overall survival was 5.79. DFS and overall survival were significantly higher among patients with corrected SUV max <6 than among patients with corrected SUVmax ≥ 6. The mean DFS for patients with corrected SUVmax <6 was 25.7 ± 11.14 months, and the mean DFS for patients with corrected SUV max ≥ 6 was 7.88 ± 7.1 months (p <0.018). Among patients with corrected SUVmax <6, none died, and the mean length of follow-up for this group was 35.2 ± 9.96 months. All of the patients who died had corrected SUVmax ≥ 6, and the overall survival for this group was 13.28 ±12.89 months (p <0.001). CONCLUSION. FDG uptake, as measured by corrected SUVmax, may be a predictive imaging biomarker for DFS and overall survival in patients with head-and-neck non-SCC.

AB - OBJECTIVE. The purpose of this article is to establish whether pretreatment 18F-FDG uptake predicts disease-free survival (DFS) and overall survival in patients with head-and-neck non-squamous cell carcinoma (SCC). MATERIALS AND METHODS. Eighteen patients (six women and 12 men; mean [± SD] age at diagnosis, 57.89 ± 13.54 years) with head-and-neck non-SCC were included. Tumor FDG uptake was measured by the maximum standardized uptake value (SUVmax) and was corrected for background liver FDG uptake to derive the corrected SUVmax. Receiver operating characteristic analyses were used to predict the optimal corrected SUVmax cutoffs for respective outcomes of DFS (i.e., absence of recurrence) and death. RESULTS. The mean corrected SUVmax of the 18 head-and-neck tumors was 5.63 ± 3.94 (range, 1.14-14.29). The optimal corrected SUVmax cutoff for predicting DFS and overall survival was 5.79. DFS and overall survival were significantly higher among patients with corrected SUV max <6 than among patients with corrected SUVmax ≥ 6. The mean DFS for patients with corrected SUVmax <6 was 25.7 ± 11.14 months, and the mean DFS for patients with corrected SUV max ≥ 6 was 7.88 ± 7.1 months (p <0.018). Among patients with corrected SUVmax <6, none died, and the mean length of follow-up for this group was 35.2 ± 9.96 months. All of the patients who died had corrected SUVmax ≥ 6, and the overall survival for this group was 13.28 ±12.89 months (p <0.001). CONCLUSION. FDG uptake, as measured by corrected SUVmax, may be a predictive imaging biomarker for DFS and overall survival in patients with head-and-neck non-SCC.

KW - F-FDG PET/CT

KW - Disease-free survival

KW - Head and neck

KW - Non-squamous cell carcinoma

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=80053246722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053246722&partnerID=8YFLogxK

U2 - 10.2214/AJR.10.4884

DO - 10.2214/AJR.10.4884

M3 - Article

VL - 197

SP - 976

EP - 980

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 4

ER -